T.Rx Capital, a newly established life sciences venture capital firm co-founded by Michael Langer, son of biotech legend Robert Langer, has closed a $77.5 million inaugural fund. The firm aims to back visionary founders operating at the crossroads of technology and biology. With experienced industry leadership including former Pear Therapeutics CEO and Eli Lilly veterans, T.Rx Capital seeks to drive innovation in biotechnology startups focusing on emerging therapies and technologies.